Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Phase III Study of M7824 vs Pembrolizumab in Stage IV Non-small Cell Lung Cancer
2018-001517-32Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing M7824 monotherapy with Pembrolizumab monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
bintrafusp alfapembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001517-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001517-32.